Baudax Bio (NASDAQ:BXRX) +10% AH, is awarded a group purchasing agreement with Premier, effective August 2020, enabling Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by the latter for ANJESO (meloxicam) injection.
The drug is for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.